Trial results for the study investigating nivolumab in combination with chemoradiation for Stage II-IVB nasopharyngeal carcinoma (NPC) were posted on ClinicalTrials.gov on 2026-01-12. The Phase 2 trial, NCT03267498, reported an Overall Response Rate (ORR) of 100% among participants receiving the combination therapy.
Background
Nivolumab is a monoclonal antibody. This Phase 2 trial explored how well nivolumab and chemoradiotherapy work together in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth by targeting specific cells. Chemoradiotherapy, which combines chemotherapy (using cisplatin) and radiation therapy, aims to prevent cancer from spreading. The study hypothesized that combining nivolumab with chemoradiotherapy could be more effective in treating this patient population.
Trial design
The study, identified as NCT03267498, was a Phase 2 trial with an overall status of COMPLETED. It enrolled 40 participants diagnosed with Nasopharyngeal Carcinoma. The interventions investigated were nivolumab and cisplatin, administered as part of a chemoradiation regimen.
Key results
The trial reported several key measurements for the Nivolumab + Chemoradiation group:
- The "Rate of Completion of All Adjuvant Immunotherapy" was 100 percentage of participants.
- The "Overall Response Rate (ORR)" was 100 percentage of participants.
- Regarding "Number of Treatment-related Adverse Events (AEs)", individual counts were reported as 1, 1, 2, 1, 11, 18, 1, 1, 1, and 1 adverse events.
What this means
The results from this Phase 2 trial indicate a high rate of treatment completion and a notable 100% Overall Response Rate for the combination of nivolumab and chemoradiation in patients with Stage II-IVB nasopharyngeal carcinoma. While the trial reported several treatment-related adverse events, the high response rate suggests potential efficacy for this regimen in this challenging cancer. These findings warrant further investigation in larger studies to confirm efficacy and fully characterize the safety profile.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03267498, titled "Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)," were posted on 2026-01-12 on clinicaltrials.gov.